Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.11
-1.3%
$20.05
$11.50
▼
$22.13
$7.36B1.242.43 million shs1.02 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$127.12
-15.8%
$158.54
$108.00
▼
$200.00
$5.12B-1.19192,464 shs888,875 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$102.11
+0.0%
$100.43
$53.38
▼
$111.86
$6.68B0.011.08 million shs636,086 shs
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$8.75
-6.5%
$10.97
$4.70
▼
$13.28
$1.49BN/A1.00 million shs1.33 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-2.37%-1.56%+7.67%+19.27%+85.43%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-3.33%-11.14%-2.22%-6.23%+25.47%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.10%+0.84%+1.70%+2.13%+93.41%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
-6.85%-15.98%-13.50%-15.29%+933,499,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.11
-1.3%
$20.05
$11.50
▼
$22.13
$7.36B1.242.43 million shs1.02 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$127.12
-15.8%
$158.54
$108.00
▼
$200.00
$5.12B-1.19192,464 shs888,875 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$102.11
+0.0%
$100.43
$53.38
▼
$111.86
$6.68B0.011.08 million shs636,086 shs
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$8.75
-6.5%
$10.97
$4.70
▼
$13.28
$1.49BN/A1.00 million shs1.33 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-2.37%-1.56%+7.67%+19.27%+85.43%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-3.33%-11.14%-2.22%-6.23%+25.47%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.10%+0.84%+1.70%+2.13%+93.41%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
-6.85%-15.98%-13.50%-15.29%+933,499,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.80
Moderate Buy$23.008.93% Upside
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.67
Moderate Buy$226.9178.50% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.21
Hold$107.445.22% Upside
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
2.00
Hold$15.0071.53% Upside

Current Analyst Ratings Breakdown

Latest TRLV, LNTH, AMRX, and BLTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetOutperform$221.00 ➝ $230.00
11/16/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetBuy$303.00 ➝ $314.00
11/13/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetOutperform$185.00 ➝ $215.00
11/10/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C+)
11/5/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOutperform$23.00 ➝ $25.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingOverweight$21.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOverweight$24.00 ➝ $25.00
11/2/2026
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
Reiterated RatingOverweight$15.00
10/29/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingBuy$24.00
10/26/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
UpgradeStrong Sell ➝ Hold
10/23/2026
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
Reiterated RatingOverweight$15.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.20B2.30$1.51 per share14.01$1.52 per share13.89
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$19.15 per shareN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.56B4.27$6.39 per share15.97$20.73 per share4.93
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$1.18B1.26N/AN/A$4.52 per share1.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4250.2718.682.494.17%283.50%7.79%N/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.73N/A174.14N/AN/A-9.95%-9.76%N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.0625.1518.14N/A17.28%29.26%15.40%N/A
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
-$116.38M$0.2043.7324.99N/A-41.22%-0.34%-0.14%N/A

Latest TRLV, LNTH, AMRX, and BLTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.7863-$0.60+$0.1863-$0.75N/AN/A
11/5/2026Q3 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.23$1.68+$0.45$0.33$355.74 million$389.91 million
11/5/2026Q3 2026
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$0.09$0.09N/AN/A$221.79 million$230.20 million
11/3/2026Q3 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.23$0.26+$0.03-$0.06N/A$862.68 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
5.61
1.87
1.24
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
26.68
26.68
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.42
3.25
3.06
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
0.45
5.52
3.65

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/A

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
3.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500348.41 million288.14 millionOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
4140.27 million34.92 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.40 million64.29 millionOptionable
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
5,000170.63 million164.17 millionOptionable

Recent News About These Companies

Trulieve Announces November 2026 Event Participation
Cannabis Stocks To Watch Now - November 9th
Trulieve Cannabis Q3 Earnings Call Highlights
Cannabis Stocks To Research - November 7th
Trulieve Reports Third Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$21.11 -0.28 (-1.29%)
Closing price 03:58 PM Eastern
Extended Trading
$21.13 +0.02 (+0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$127.12 -23.90 (-15.83%)
Closing price 03:58 PM Eastern
Extended Trading
$127.12 0.00 (0.00%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$102.11 +0.01 (+0.01%)
Closing price 03:59 PM Eastern
Extended Trading
$102.10 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Trulieve Cannabis stock logo

Trulieve Cannabis NYSE:TRLV

$8.74 -0.61 (-6.47%)
Closing price 03:58 PM Eastern
Extended Trading
$8.98 +0.24 (+2.70%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.